No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Jubilant Pharmova Limited functions as a comprehensive pharmaceutical enterprise with a global footprint, structured into three primary divisions: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment is involved in a range of activities, including the production and distribution of allergy treatments, outsourced manufacturing of both sterile injectable and non-sterile medications, the creation of active pharmaceutical ingredients (APIs), and solid dose formulations. This division also markets radiopharmaceuticals through a network of 48 specialized pharmacies located across the United States. Its Contract Research & Development Services arm offers collaborative scientific investigation to pioneering pharmaceutical companies. Furthermore, the Proprietary Novel Drugs segment focuses on developing innovative therapies for conditions such as cancer and autoimmune diseases. Established in 1978 and headquartered in Noida, India, the company was formerly named Jubilant Life Sciences Limited before adopting its current designation, Jubilant Pharmova Limited, in February 2021.
www.jubilantpharmova.comNo one on the platform currently holds JUBLPHARMA.NS.
No tracked institution reports a position in JUBLPHARMA.NS as of their last filing.
No one on the platform has traded JUBLPHARMA.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.6% | 3.4% | 15.1% | — | — | — |
| Rev. Growth % | 14.4% | 6.3% | ||||
| Profit Margin % | 4.8% | 4.7% | 7.7% | |||
| Free Cash Flow Margin % | -5.3% | -0.7% | 6.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $93.4B | +15.3% | $40.50 | $34.73–$46.27 | — | 2 |
| 2028 | $105.4B | +12.9% | $57.63 | $54.72–$60.53 | — | 2 |
| 2029 | $112.6B | +6.8% | $58.50 | $57.75–$59.25 | — | 1 |
| 2030 | $130.8B | +16.1% | $63.20 | $62.39–$64.01 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | $5.80 | $3.53 | -39.1% |
| 2026-05-22 | $7.45 | $7.80 | +4.7% |
| 2026-02-06 | $8.25 | $5.00 | -39.4% |
| 2025-10-31 | $6.85 | $7.80 | +13.9% |
| 2025-07-29 | $6.40 | $6.50 | +1.6% |
| 2025-05-16 | $8.50 | $9.75 | +14.7% |
| 2025-01-31 | $6.10 | $7.30 | +19.7% |
| 2024-10-25 | $4.90 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| JUBLPHARMA.NSJubilant Pharmova Limited | $1000.85 | -1.10% | $158.5B | — |
| APLLTD.BOAlembic Pharmaceuticals Limited | $825.55 | +0.38% | $162.2B | — |
| APLLTD.NSAlembic Pharmaceuticals Limited | $824.00 | -0.09% | $162.0B | — |
| CAPLIPOINT.NSCaplin Point Laboratories Limited | $2581.00 | +0.40% | $196.2B | — |
| ERIS.BOEris Lifesciences Limited |
| $7.10 |
| +44.9% |
| $1296.30 |
| -1.12% |
| $179.7B |
| — |
| ERIS.NSEris Lifesciences Limited | $1296.80 | -1.02% | $179.7B | — |
| GRANULES.BOGranules India Limited | $856.75 | -1.81% | $213.3B | — |
Source: Financial Modeling Prep · peers by sector/industry